Interaction Checker

Interaksi Pomalidomid

Pomalidomid (Pomalyst) memiliki 29 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 9 mayor, 20 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (9)

  • Deferasirokssuplemen zat besiMayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (label Pomalidomid, Peringatan dan perhatian)

  • FluvoksaminSSRIMayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • Kanabidiol (obat resep)antikonvulsanMayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • MeksiletinantiaritmiaMayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • SiprofloksasinfluorokuinolonMayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • Viloksazinpenghambat ambilan kembali norepinefrinMayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

  • Zileutonpenghambat CYP1A2Mayor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (label Pomalidomid, Interaksi obat)

Interaksi moderat (20)

  • ApiksabanantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • ArgatrobanantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • BivalirudinantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • DabigatranantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • Desogestrel dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • EdoksabanantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • EnoksaparinantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • Estradiol dan dienogestkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • Etinodiol diasetat dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • FondaparinuksantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • HeparinantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • NoretisteronprogestinModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • Noretisteron dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • Norgestimat dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • Norgestrel dan etinilestradiolkontrasepsi oralModerat

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (label Pomalidomid, Peringatan dan perhatian)

  • RivaroksabanantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

  • Tembakau dan merokokTembakau dan ganjaModerat

    Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (label Pomalidomid, Peringatan dan perhatian)

  • WarfarinantikoagulanModerat

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (label Pomalidomid, Peringatan dan perhatian)

Periksa Pomalidomid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.